NCT01213199已完成2 期
Efficacy and Safety of Adapalene Gel 0.3% in the Treatment of Atrophic Acne Scars. A Pilot Study.
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Galderma R&D
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Global Scarring Severity
研究概览
简要总结
The purpose of this study is to assess the efficacy and safety of Adapalene Gel 0.3% in the treatment of atrophic acne scars.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female subjects of any race, aged 18 to 50 years inclusive
- •Subjects with a past history of acne and with moderate to severe facial atrophic acne scars
排除标准
- •Subjects with active inflammatory acne lesions
- •Subjects with hypertrophic acne scars
研究组 & 干预措施
Differin 0.3%
Experimental
Differin® 0.3% Gel
Adapalene 0.3%
Topical to the face, once daily application in the evening for the first four weeks and twice daily application in the morning and in the evening for the following 20 weeks.
干预措施: Adapalene (Drug)
结局指标
主要结局
Global Scarring Severity
时间窗: Week 24
Grade Level: 1. Macular disease 2. Mild disease 3. Moderate disease 4. Severe disease
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Bioequivalence Study of Adapalene Gel 0.3% in Subjects With Facial Acne VulgarisAcne VulgarisNCT03650361Aleor Dermaceuticals Limited755
已完成
3 期
Adapalene Gel 0.3% Versus Tretinoin 0.05% Emollient Cream for Treatment of PhotodamagePhotoagingNCT00647556Galderma R&D30
已完成
4 期
Evaluation of Efficacy and Safety of Adapalene 0.1%/Benzoyl Peroxide 2.5% Gel in the Treatment of Acne VulgarisAcne VulgarisNCT01149330Galderma Brasil Ltda.75
尚未招募
Unknown
Comparison of safety and effectiveness in between topical Adapalene plus clindamycin and topical Adapalene plus benzoyl peroxide for treatment of inflammatory Acne vulgarisCTRI/2024/02/062423DR SOUMIK BISWAS
已完成
3 期
A Comparative Study of Adapalene Gel,0.3% Versus Tretinoin Emollient Cream, 0.05% for the Treatment of PhotoagingPhotodamagePhotoagingNCT01406080Galderma Brasil Ltda.128